Zhonghui Bio-B (02627.HK): Proposal to Dissolve the Board of Supervisors

Gelonghui, April 19th - ZH Bio-B (02627.HK) announced that, in accordance with the 'Company Law of China' and other applicable laws, regulations, and normative documents, and taking into account the actual situation of the company, the board of directors proposed to dissolve the board of supervisors, subject to shareholder review and approval. The functions and powers of the board of supervisors as stipulated under the 'Company Law of China' will be assumed by the company’s audit committee. Accordingly, the positions of the current supervisors will be terminated, and the rules of procedure for the board of supervisors meetings will be abolished.

Gelonghui FinanceApr 19 19:45

ZH Bio-B (02627) Adjusts Members of Strategic Committee

Zhonghui Bio-B (02627) announced that the board of directors has reviewed and approved the adjustment of the members of the company’s board strategic committee, effective as of the date of board approval. The adjusted membership is as follows: Chairman: Mr. An Youcai; Members: Mr. He Yiming, Mr. Li Xiangming.

Zhitong FinanceApr 19 19:38

The first and only trivalent influenza virus subunit vaccine for the entire population is steadily advancing in nationwide procurement, contributing to global influenza prevention and control efforts by 2026!

Recently, Jiangsu Zhonghui Yuan Tong Biotechnology Co., Ltd. (referred to as 'Zhonghui Biotech', 02627) has announced further positive developments in the market.

Zhitong FinanceApr 14 16:29

Zhonghui Biotech (02627): Monkeypox mRNA vaccine application accepted, partnering with Chongqing CDC to enhance innovation capabilities

Recently, Zhonghui Bio (02627) has achieved several breakthrough advancements in corporate innovation and development. The clinical trial application for its self-developed Class I new drug, a monkeypox mRNA vaccine, has been accepted by the Center for Drug Evaluation under the National Medical Products Administration of China.

Zhitong FinanceApr 1 08:33

Zhonghui Bio-B (02627) has suspended trading as of April 1, pending the release of its 2025 annual results.

Zhonghui Bio-B (02627) announced that trading of the company’s shares will be suspended on the Stock Exchange at 9:00 a.m. on Wednesday, April 1, 2026, until the company releases its 2025 annual results.

Zhitong FinanceApr 1 08:29

AB&B BIO-TECH-B: INSIDE INFORMATION:(1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2025;(2) POSTPONEMENT OF BOARD MEETING; AND(3) SUSPENSION OF TRADING

HKEXApr 1 08:14 · Announcements